Browse Trials
Find Breast Cancer Clinical Trials That Are Right For You
The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.
Use the search box and filters to find a trial that’s right for you.
Currently viewing trials
(Last updated: November 22, 2023)
Brain Mets
BRCA1/2 (inherited)
Chemotherapy
Hormone Therapy
Leptomeningeal Disease
Radiation Oncology
Surgery
Surgery: Reconstruction
Targeted Therapy: All
Targeted Therapy: ADC
Targeted Therapy: Anti-HER2 Therapy
Targeted Therapy: CDK Inhibitors
Targeted Therapy: PARP Inhibitors
Targeted Therapy: Tumor Mutations
Targeted Therapy: Other Targeted Therapy
Vaccines and Immunotherapy
Other Treatment
Activities
Complementary and Integrative Medicine
Decision Support
Diagnosing Breast Cancer
Genetics/Family History
Having Children
Healthy/High Risk
Imaging
Lymphedema
Managing Side Effects
No Travel Required
Predicting Response to Treatment
Preventing Breast Cancer
Preventing Recurrence
Support/Education
Surveys/Interviews/Registries
AKT
ALK
AR
BARD1
BRCA1/2 (tumor)
BRIP1
CD205
CD70
CHEK2 or CHEK1
dMMR/MSI-H
ESR1
FGFR
HER2/ERBB2
HLA
MET or C-Met
NTRK
PALB2
PIK3CA or PI3K
PTEN
RAD51
RAF (including BRAF)
RAS (KRAS or NRAS)
RB
ROS1
TP53
NEAREST SITE: 3 miles
University of California, San Francisco
San Francisco,CA
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT05239143
P-MUC1C-ALLO1 CAR-T Cell Immunotherapy for Advanced Breast Cancer
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will be assigned <span class="highlight">to</span> 1 of 2 groups based on when you enroll: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 CAR-T cell immunotherapy, by IV, 1 session</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 CAR-T cell immunotherapy, by IV, multiple sessions</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">May require 1 biopsy</li> <li class="seamTextUnorderedListItem">Rimiducid (CaspaCIDe®) may be given for safety</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">P-MUC1C-ALLO1 is an experimental immunotherapy called CAR-T cell <span class="highlight">therapy.</li></span> <li class="seamTextUnorderedListItem">Allogeneic CAR-T cell <span class="highlight">therapy</span> is an immunotherapy made from donor immune cells.</li> <li class="seamTextUnorderedListItem">Donor immune cells are modified with chimeric antigen receptors (CARs) so <span class="highlight">they</span> can attack cancer cells.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cells</span> are <span class="highlight">then</span> infused back into you while you are hospitalized.</li> <li class="seamTextUnorderedListItem">Rimiducid (CaspaCIDe®) is an enzyme <span class="highlight">that</span> can be administered for safety <span class="highlight">to</span> kill CAR-T cells, if needed.</li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05239143' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://poseida.com/science/pipeline/#cart-therapies' target='_blank'>Poseida Therapeutics Drug Information Page: P-MUC1C-ALLO1</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-p-muc1c-allo1-a-fully-allogeneic-car-t-targeting-multiple-solid-tumors-301447910.html' target='_blank'>Poseida Therapeutics Press Release: P-MUC1C-ALLO1</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bellicum.com/caspacide-safety-switch/' target='_blank'>Bellicum Phamaceuticals Drug Information Page: Rimiducid (CaspaCIDe®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.frontiersin.org/articles/10.3389/fimmu.2020.618427/full' target='_blank'>Journal Article: Allogeneic CAR T-Cell Immunotherapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 339 miles
University of California, Los Angeles
Santa Monica,CA
VISITS: Hospital stay may be required
PHASE: I
NCT ID: NCT05274451
LYL797 CAR T-Cell Immunotherapy for Triple Negative, ROR1 Positive Advanced Breast Cancer
A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LYL797 <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Additional Procedures</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Requires 1 biopsy</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">LYL797 is an experimental <span class="highlight">type</span> of immunotherapy called <span class="highlight">CAR</span> <span class="highlight">T-cell/CAR-T</span> <span class="highlight">therapy.</li></span> <li class="seamTextUnorderedListItem">CAR-T or <span class="highlight">CAR</span> <span class="highlight">T</span> cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) <span class="highlight">that</span> allow <span class="highlight">them</span> <span class="highlight">to</span> attack proteins on cancer cells, and <span class="highlight">then</span> put back in your body.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> being used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack ROR1 positive cancer cells</li> <li class="seamTextUnorderedListItem">This study is also enrolling patients with other <span class="highlight">types</span> of ROR1 positive cancers.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ROR1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05274451' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://lyell.com/our-pipeline' target='_blank'>Lyell Immunopharma Drug Information Page: LYL797</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.dana-farber.org/cellular-therapies-program/car-t-cell-therapy/faq-about-car-t-cell-therapy/' target='_blank'>Dana-Farber Cancer Institute: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy#section-adoptive-cell-therapy' target='_blank'>Breastcancer.org: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT03696030
CAR T-Cell Immunotherapy in HER2+ Breast Cancer with Brain or Leptomeningeal Metastases
A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and/or Leptomeningeal Metastases From HER2 Positive Cancers Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw <span class="highlight">to</span> collect white blood cells <span class="highlight">to</span> make your HER2 <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Surgery <span class="highlight">to</span> place a device (similar <span class="highlight">to</span> a chemotherapy port) under your scalp</li> <li class="seamTextUnorderedListItem">HER2 <span class="highlight">CAR</span> <span class="highlight">T-cells,</span> by injection, weekly, 3 <span class="highlight">times</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i> </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Follow up</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Every 2 months for 1 year, <span class="highlight">then</span> every year for 15 years</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leptomeningeal metastases are when cancer spreads <span class="highlight">to</span> <span class="highlight">the</span> membranes surrounding <span class="highlight">the</span> brain and/or <span class="highlight">the</span> spinal cord (leptomeninges) or <span class="highlight">to</span> <span class="highlight">the</span> cerebrospinal fluid.</li> <li class="seamTextUnorderedListItem">CAR-T or <span class="highlight">CAR</span> <span class="highlight">T</span> cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so <span class="highlight">that</span> <span class="highlight">they</span> can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cells</span> are <span class="highlight">then</span> infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> being used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">You will have surgery <span class="highlight">to</span> insert a device under your scalp so <span class="highlight">that</span> <span class="highlight">the</span> <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> can be infused directly into your brain.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03696030' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cityofhope.org/physician-news/breast-cancer-car-t-cell-therapy' target='_blank'>City of Hope Trial Information</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-cell Therapy and Its Side Effects</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li></ul>
NEAREST SITE: 353 miles
City of Hope Medical Center
Duarte,CA
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT04020575
CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for MUC 1*
Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer With Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw <span class="highlight">to</span> collect white blood cells <span class="highlight">to</span> make your personalized <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Chemotherapy <span class="highlight">to</span> deplete your lymph cells</li> <li class="seamTextUnorderedListItem">huMNC2-CAR44 <span class="highlight">CAR</span> <span class="highlight">T-cells,</span> by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR <span class="highlight">T</span> cell or CAR-T cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so <span class="highlight">that</span> <span class="highlight">they</span> can attack a specific protein. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cells</span> are <span class="highlight">then</span> infused back into you while you are hospitalized </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> being used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack MUC1 on cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04020575' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/research/car-t-cells' target='_blank'>NCI: Car T-Cells</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.minervabio.com/clinical-trial-humnc2-car44-in-mbc/' target='_blank'>Minerva Biotechnologies: Study Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 353 miles
City of Hope National Medical Center
Duarte,CA
VISITS: May require hospitalization, 10 visits over 13 months
PHASE: I
NCT ID: NCT04660929
CAR-T Immunotherapy for Advanced HER2 Positive Breast Cancer
A Phase 1, First in Human Study of Adenovirally Transduced Autologous Macrophages Engineered to Contain an Anti-HER2 Chimeric Antigen Receptor in Subjects With HER2 Overexpressing Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw <span class="highlight">to</span> collect white blood cells <span class="highlight">to</span> make your personalized <span class="highlight">CAR</span> <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">CT-0508, by IV, 1 or 3 <span class="highlight">times,</span> over 1 week</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CT-0508 is a CAR-T immunotherapy made from your own immune cells.</li> <li class="seamTextUnorderedListItem">CAR-T/CAR <span class="highlight">T-cell</span> <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">First, your immune cells are removed from your body during a process called leukapheresis. </li> <li class="seamTextUnorderedListItem">Then <span class="highlight">the</span> immune cells are modified with chimeric antigen receptors (CARs) so <span class="highlight">they</span> can attack HER2 proteins on cancer cells.</li> <li class="seamTextUnorderedListItem">Finally, <span class="highlight">the</span> modified immune cells are <span class="highlight">then</span> infused back into your body. <span class="highlight">This</span> part of <span class="highlight">the</span> <span class="highlight">trial</span> may include a hospital stay. </li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of HER2 positive cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04660929' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://carismatx.com/science/' target='_blank'>Carisma Therapeutics Drug Information Page: CT-0508</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 1643 miles
Houston Methodist Hospital
Houston,TX
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT03635632
CAR T-Cell Therapy for Advanced Breast Cancer That Tests Positive for GD2
Phase I Study of Autologous T Lymphocytes Expressing GD2-specific Chimeric Antigen and Constitutively Active IL-7 Receptors for the Treatment of Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Solid Cancers (GAIL-N) Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draw <span class="highlight">to</span> collect white blood cells <span class="highlight">to</span> make your personalized <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> (leukapheresis)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®) and fludarabine (Fludara®), by IV, at least 24 hours before <span class="highlight">the</span> <span class="highlight">CAR</span> <span class="highlight">T-cell</span> immunotherapy is given</li> <li class="seamTextUnorderedListItem">C7R-GD2 <span class="highlight">CAR</span> <span class="highlight">T-cell</span> immunotherapy, by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR <span class="highlight">T-cell</span> <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells. <span class="highlight">The</span> white blood cells are removed from your body and <span class="highlight">then</span> modified with chimeric antigen receptors (CARs) so <span class="highlight">they</span> can attack specific proteins. <span class="highlight">These</span> white blood cells are <span class="highlight">then</span> infused into your body. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack cancer cells <span class="highlight">that</span> <span class="highlight">test</span> positive for <span class="highlight">the</span> protein GD2.</li> <li class="seamTextUnorderedListItem">You will receive <span class="highlight">the</span> chemotherapy drugs cyclophosphamide (Cytoxan®) and fludarabine (Fludara®) before you receive <span class="highlight">the</span> <span class="highlight">CAR</span> <span class="highlight">T-cells.</span> <span class="highlight">This</span> makes it easier for <span class="highlight">the</span> <span class="highlight">CAR</span> <span class="highlight">T-cells</span> <span class="highlight">to</span> get into your immune system. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other <span class="highlight">types</span> of advanced cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: GD2</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03635632' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.bcm.edu/research/clinical-trials/h-42207' target='_blank'>Baylor College of Medicine Study Page: GAIL-N</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-terms/def/car-t-cell-therapy' target='_blank'>NCI Dictionary of Cancer Terms: CAR T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/treatment-options/car-t-cell-therapy.html' target='_blank'>MD Anderson Cancer Center: T-Cell Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5458232/' target='_blank'>Journal Article: GD2 Expression in Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 1643 miles
Baylor St. Luke's Medical Center
Houston,TX
VISITS: May require hospital stay
PHASE: I
NCT ID: NCT03740256
CAR-T Cell Immunotherapy & Immunotherapy Injected Directly into Tumors for Metastatic HER2 Positive Breast Cancer
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAdVEC, by injection directly into a <span class="highlight">tumor,</span> one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> followed by </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2-specific CAR-T Cell <span class="highlight">therapy,</span> by IV, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule. Hospital stay may be required.</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR-T is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">The cells are removed from your blood, modified with chimeric antigen receptors (CARs) <span class="highlight">that</span> allow <span class="highlight">them</span> <span class="highlight">to</span> attack proteins on cancer cells, and <span class="highlight">then</span> put back in your body.</li> <li class="seamTextUnorderedListItem">CAdVEC is an oncolytic adenovirus--this means it <span class="highlight">targets</span> and kills cancer cells. It may directly kill cancer cells and stimulate your immune system <span class="highlight">to</span> go after and kill cancer cells.</li> <li class="seamTextUnorderedListItem">CAdVEC is injected directly into a <span class="highlight">tumor.</span> </li> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of HER2 positive cancer.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03740256' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li><li class='seamTextUnorderedListItem'><a href='https://ncit.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=20.07d&code=C158743&ns=ncit&type=all&key=null&b=1&n=0&vse=null' target='_blank'>NCI Thesaurus: CAdVEC</a> </li></ul>
NEAREST SITE: 2395 miles
Moffitt Cancer Center
Tampa,FL
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT05694364
PRGN-3007 CAR T Cell Therapy for Advanced Triple Negative, ROR-1 Positive Breast Cancer
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cyclophosphamide (Cytoxan®)</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRGN-3007 <span class="highlight">CAR</span> <span class="highlight">T-cells</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PRGN-3007 CAR-T or <span class="highlight">CAR</span> <span class="highlight">T</span> cells are an experimental personalized immunotherapy made from your white blood cells. <span class="highlight">The</span> white blood cells are removed from your body and <span class="highlight">then</span> modified with chimeric antigen receptors (CARs) so <span class="highlight">they</span> can attack specific proteins. <span class="highlight">These</span> white blood cells are <span class="highlight">then</span> infused into your body.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack cancer cells <span class="highlight">that</span> <span class="highlight">test</span> positive for <span class="highlight">the</span> protein ROR-1.</li> <li class="seamTextUnorderedListItem">Before you receive PRGN-3007 <span class="highlight">T-cells,</span> you will be given <span class="highlight">the</span> chemotherapy drug cyclophosphamide (Cytoxan®) <span class="highlight">to</span> prepare your immune system <span class="highlight">to</span> receive <span class="highlight">the</span> immunotherapy.</li> <li class="seamTextUnorderedListItem">Leukapheresis is a procedure <span class="highlight">to</span> collect your white blood cells <span class="highlight">to</span> make your personalized <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy.</li></span> <li class="seamTextUnorderedListItem">This <span class="highlight">trial</span> is also enrolling people with other <span class="highlight">types</span> of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ROR-1</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05694364' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://precigen.com/pipeline/' target='_blank'>Precigen: PRGN-3007 Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/drugs/cytoxan' target='_blank'>Breastcancer.org: Cyclophosphamide (Cytoxan®)</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapies/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies for MBC</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html' target='_blank'>American Cancer Society: CAR T-Cell Therapy</a> </li></ul>
NEAREST SITE: 2432 miles
National Institutes of Health Clinical Center
Bethesda,MD
VISITS: Hospital stay for at least 1 week; follow-up visits for 2 years
PHASE: I-II
NCT ID: NCT02830724
CAR T-Cell Immunotherapy for Metastatic Breast Cancer That Tests Positive for CD70
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Hospital stay (at least 1-week):</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Leukapheresis (blood draw for <span class="highlight">the</span> collection of cells)</li> <li class="seamTextUnorderedListItem">Cyclophosphamide, by IV, once a day, for 2 days</li> <li class="seamTextUnorderedListItem">Fludarabine, by IV, once a day, for 5 days</li> <li class="seamTextUnorderedListItem">Aldesleukin, by IV, 3 <span class="highlight">times</span> a day, for 3 days</li> <li class="seamTextUnorderedListItem">Anti-hCD70 <span class="highlight">CAR</span> <span class="highlight">T-cells,</span> by IV, one <span class="highlight">time</span></li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Post-hospital stay:</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Antibiotic for 6 months</li> <li class="seamTextUnorderedListItem">Repeat Leukapheresis (blood draw for <span class="highlight">the</span> collection of cells)</li> <li class="seamTextUnorderedListItem">1-2 day hospital visits (for lab <span class="highlight">tests,</span> imaging studies, and a physical exam), every 1-3 months for <span class="highlight">the</span> 1st year after <span class="highlight">treatment,</span> every 6 months for <span class="highlight">the</span> 2nd year, and <span class="highlight">then</span> as determined by your doctor</li></ul>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">CAR <span class="highlight">T-cell</span> is a personalized immunotherapy made from your white blood cells. </li> <li class="seamTextUnorderedListItem">After your blood cells are removed, <span class="highlight">they</span> are modified with chimeric antigen receptors (CARs) so <span class="highlight">they</span> can attack specific proteins. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cells</span> are <span class="highlight">then</span> infused back into you while you are hospitalized. </li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T-cell</span> <span class="highlight">therapy</span> used in <span class="highlight">this</span> study is designed <span class="highlight">to</span> get <span class="highlight">the</span> immune system <span class="highlight">to</span> see and kill cancer cells <span class="highlight">that</span> are CD70+. </li> <li class="seamTextUnorderedListItem">Along with <span class="highlight">the</span> CAR-T immunotherapy, you will receive <span class="highlight">the</span> chemotherapy drugs fludarabine and cyclophosphamide. <span class="highlight">These</span> drugs are given <span class="highlight">to</span> deplete <span class="highlight">the</span> lymph cells. </li> <li class="seamTextUnorderedListItem">You will also receive aldesleukin, a drug <span class="highlight">that</span> stimulates <span class="highlight">the</span> growth and development of <span class="highlight">T</span> cells.</li> <li class="seamTextUnorderedListItem">Targets or mutations: CD70</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02830724' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.drsusanloveresearch.org/videos/chimeric-antigen-receptor-t-cell-car-t-therapy' target='_blank'>Dr Susan Love Research Foundation: CAR-T Therapy</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pubmed/25368676' target='_blank'>Journal Article Abstract: CD70, A Potential Target in Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/search?contains=false&q=Aldesleukin' target='_blank'>NCI Drug Dictionary: Aldesleukin</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/what-is-car-t-therapy/' target='_blank'>Metastatic Trial Talk: What is CAR-T Therapy?</a> </li></ul>
NEAREST SITE: 2517 miles
University of Pennsylvania
Philadelphia,PA
VISITS: May require hospitalization
PHASE: I
NCT ID: NCT05623488
CAR T Cell Therapy for Advanced Triple Negative, Mesothelin Expressing Breast Cancer
Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer Scientific Title
- What's involved?
- What's being studied?
- How can I learn more?
-
<p class="seamTextPara"> You will receive <span class="highlight">the</span> following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mesothelin expression <span class="highlight">testing</span> on your <span class="highlight">tumor</span></li> <li class="seamTextUnorderedListItem">huCART-meso cells</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for <span class="highlight">treatment</span> schedule</i></p>
-
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">huCART-meso is an experimental immunotherapy called <span class="highlight">CAR</span> <span class="highlight">T</span> cell <span class="highlight">therapy.</li></span> <li class="seamTextUnorderedListItem">CAR-T or <span class="highlight">CAR</span> <span class="highlight">T</span> cell <span class="highlight">therapy</span> is a personalized immunotherapy made from your white blood cells.</li> <li class="seamTextUnorderedListItem">Your blood cells are removed and modified in a lab with chimeric antigen receptors (CARs) so <span class="highlight">that</span> <span class="highlight">they</span> can attack a specific protein.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span> cells are <span class="highlight">then</span> infused back into you while you are hospitalized.</li> <li class="seamTextUnorderedListItem">The <span class="highlight">CAR</span> <span class="highlight">T</span> cell <span class="highlight">therapy</span> being used in <span class="highlight">this</span> study <span class="highlight">trains</span> <span class="highlight">the</span> immune system <span class="highlight">to</span> attack mesothelin expressing cancer cells.</li></ul>
-
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05623488' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/adoptive-cell-therapy-2-2/' target='_blank'>Metastatic Trial Talk: Adoptive Cell Therapies: A Type of Immunotherapy for MBC</a> </li></ul>